UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CTXR The NASDAQ Capital Market FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38174 Citius Pharmaceuticals ...

PART I. FINANCIAL INFORMATION [Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20%28Unaudited%29) Unaudited financial statements for June 30, 2022, show a **$25.6 million** net loss and **$48.0 million** cash, driven by increased R&D [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2022, total assets decreased to **$120.3 million**, and total equity declined to **$110.3 million** Condensed Consolidated Balance Sheet Highlights (Unaudited) | Balance Sheet Item | June 30, 2022 | September 30, 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $48,044,194 | $70,072,946 | | Total Current Assets | $50,834,513 | $72,814,350 | | Total Assets | $120,315,795 | $142,429,059 | | Total Current Liabilities | $4,461,122 | $3,982,292 | | Total Liabilities | $9,979,805 | $9,646,326 | | Total Equity | $110,335,990 | $132,782,733 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the nine months ended June 30, 2022, the company reported a **$25.6 million** net loss, driven by increased R&D Statement of Operations Summary (Unaudited) | Metric | Nine Months Ended June 30, 2022 | Nine Months Ended June 30, 2021 | | :--- | :--- | :--- | | Revenues | $0 | $0 | | Research and development | $13,798,251 | $9,946,268 | | General and administrative | $9,038,949 | $7,389,269 | | Stock-based compensation | $2,929,279 | $993,114 | | **Operating Loss** | **($25,766,479)** | **($18,328,651)** | | **Net Loss** | **($25,649,906)** | **($18,093,349)** | | **Net Loss Per Share** | **($0.18)** | **($0.20)** | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was **$22.0 million**, ending the period with **$48.0 million** in cash Cash Flow Summary (Unaudited) | Cash Flow Activity | Nine Months Ended June 30, 2022 | Nine Months Ended June 30, 2021 | | :--- | :--- | :--- | | Net Cash Used In Operating Activities | ($22,028,752) | ($18,659,384) | | Net Cash Used In Investing Activities | $0 | ($6,938) | | Net Cash Provided By Financing Activities | $0 | $120,470,550 | | **Net Change in Cash** | **($22,028,752)** | **$101,804,228** | | **Cash at End of Period** | **$48,044,194** | **$115,663,976** | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the company's critical care product focus, liquidity, and key license agreements - The company is a specialty pharmaceutical firm focused on anti-infective products in adjunct cancer care, prescription products, and stem cell therapy. Key assets include IPR&D for Mino-Lok (**$19.4M**) and I/ONTAK (**$40M**)[26](index=26&type=chunk)[29](index=29&type=chunk) - The company has sufficient cash to fund operations through August 2023. Continued operations beyond this date depend on raising additional capital or generating revenue from product approvals (Mino-Lok or I/ONTAK)[39](index=39&type=chunk)[40](index=40&type=chunk) - The company has several key license agreements: Mino-Lok with NAT, Mino-Wrap with the University of Texas, a cellular therapy via its subsidiary NoveCite with Novellus (now Brooklyn ImmunoTherapeutics), and I/ONTAK via an agreement with Dr. Reddy's/Eisai[42](index=42&type=chunk)[45](index=45&type=chunk)[50](index=50&type=chunk) - As of June 30, 2022, the company has reserved **53,299,589 shares** of common stock for future issuances related to outstanding stock options (**9.4M**), available stock plan grants (**3.9M**), and outstanding warrants (**40.0M**)[90](index=90&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes the increased net loss to higher R&D and G&A expenses, with working capital sufficient until August 2023 - The company is a late-stage biopharmaceutical firm focused on critical care products, including Mino-Lok, Mino-Wrap, Halo-Lido, I/ONTAK, and a cellular therapy for ARDS through its subsidiary NoveCite[101](index=101&type=chunk)[104](index=104&type=chunk)[105](index=105&type=chunk) Comparison of Operating Results (Three Months Ended June 30) | Expense Category | 2022 | 2021 | Change | | :--- | :--- | :--- | :--- | | Research & Development | $4,888,192 | $2,203,748 | +$2,684,444 | | General & Administrative | $3,024,783 | $3,407,088 | -$382,305 | | Stock-based Compensation | $1,003,677 | $373,570 | +$630,107 | | **Net Loss** | **($8,863,632)** | **($5,824,008)** | **+$3,039,624** | Comparison of Operating Results (Nine Months Ended June 30) | Expense Category | 2022 | 2021 | Change | | :--- | :--- | :--- | :--- | | Research & Development | $13,798,251 | $9,946,268 | +$3,851,983 | | General & Administrative | $9,038,949 | $7,389,269 | +$1,649,680 | | Stock-based Compensation | $2,929,279 | $993,114 | +$1,936,165 | | **Net Loss** | **($25,649,906)** | **($18,093,349)** | **+$7,556,557** | - The increase in R&D expenses is primarily due to costs for the I/ONTAK product candidate (**$6.5M** for nine months), start-up costs for the Halo-Lido Phase 2b trial, and expansion of the Mino-Lok Phase 3 trial[133](index=133&type=chunk)[134](index=134&type=chunk)[136](index=136&type=chunk) - With working capital of approximately **$46.4 million** and cash of **$48.0 million** at June 30, 2022, the company projects it has sufficient funds for operations through August 2023[147](index=147&type=chunk)[148](index=148&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=24&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) This section is not applicable to the company - Not applicable[154](index=154&type=chunk) [Controls and Procedures](index=24&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of June 30, 2022, with no material internal control changes - The Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective as of June 30, 2022[156](index=156&type=chunk) - No changes in internal control over financial reporting occurred during the quarter ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, internal controls[157](index=157&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=25&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no legal proceedings - None[160](index=160&type=chunk) [Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors) There have been no changes to the company's risk factors since its Form 10-K filed on December 15, 2021 - There has been no change in the Company's risk factors since the Form 10-K filed with the SEC on December 15, 2021[161](index=161&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=25&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities - None[162](index=162&type=chunk) [Other Information](index=25&type=section&id=Item%205.%20Other%20Information) The company reports no other information - None[165](index=165&type=chunk) [Exhibits](index=26&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the report, including officer certifications and Inline XBRL data files - The report includes certifications from the Principal Executive Officer and Principal Financial Officer, as well as Inline XBRL documents[167](index=167&type=chunk)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-38174 Citius Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | --- | --- | |------- ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Nevada 27-3425913 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common stock, $0.001 par value CTXR Nasdaq Capital Market Warrants to purchase common stock CTXRW Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ende ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CTXR The NASDAQ Capital Market Warrants to purchase Common Stock CTXRW The NASDAQ Capital Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 F ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-38174 Citius Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | --- | --- | |-------- ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-38174 Citius Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | --- | --- | |------- ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Nevada 27-3425913 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common stock, $0.001 par value CTXR Nasdaq Capital Market Warrants to purchase common stock CTXRW Nasdaq Capital Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ FORM 10-Q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CTXR The NASDAQ Capital Market Warrants to purchase Common Stock CTXRW The NASDAQ Capital Market FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE A ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Nevada 27-3425913 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common stock, $0.001 par value CTXR Nasdaq Capital Market Warrants to purchase common stock CTXRW Nasdaq Capital Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ FORM 10-Q ...